Novel Majeed Syndrome-Causing LPIN2 Mutations Link Bone Inflammation to Inflammatory M2 Macrophages and Accelerated Osteoclastogenesis

Arthritis Rheumatol. 2021 Jun;73(6):1021-1032. doi: 10.1002/art.41624. Epub 2021 May 9.

Abstract

Objective: To identify novel heterozygous LPIN2 mutations in a patient with Majeed syndrome and characterize the pathomechanisms that lead to the development of sterile osteomyelitis.

Methods: Targeted genetic analysis and functional studies assessing monocyte responses, macrophage differentiation, and osteoclastogenesis were conducted to compare the pathogenesis of Majeed syndrome to interleukin-1 (IL-1)-mediated diseases including neonatal-onset multisystem inflammatory disease (NOMID) and deficiency of the IL-1 receptor antagonist (DIRA).

Results: A 4-year-old girl of mixed ethnic background presented with sterile osteomyelitis and elevated acute-phase reactants. She had a 17.8-kb deletion on the maternal LPIN2 allele and a splice site mutation, p.R517H, that variably spliced out exons 10 and 11 on the paternal LPIN2 allele. The patient achieved long-lasting remission receiving IL-1 blockade with canakinumab. Compared to controls, monocytes and monocyte-derived M1-like macrophages from the patient with Majeed syndrome and those with NOMID or DIRA had elevated caspase 1 activity and IL-1β secretion. In contrast, lipopolysaccharide-stimulated, monocyte-derived, M2-like macrophages from the patient with Majeed syndrome released higher levels of osteoclastogenic mediators (IL-8, IL-6, tumor necrosis factor, CCL2, macrophage inflammatory protein 1α/β, CXCL8, and CXCL1) compared to NOMID patients and healthy controls. Accelerated osteoclastogenesis in the patient with Majeed syndrome was associated with higher NFATc1 levels, enhanced JNK/MAPK, and reduced Src kinase activation, and partially responded to JNK inhibition and IL-1 (but not IL-6) blockade.

Conclusion: We report 2 novel compound heterozygous disease-causing mutations in LPIN2 in an American patient with Majeed syndrome. LPIN2 deficiency drives differentiation of proinflammatory M2-like macrophages and enhances intrinsic osteoclastogenesis. This provides a model for the pathogenesis of sterile osteomyelitis which differentiates Majeed syndrome from other IL-1-mediated autoinflammatory diseases.

Trial registration: ClinicalTrials.gov NCT02974595.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural

MeSH terms

  • Anemia, Dyserythropoietic, Congenital / drug therapy
  • Anemia, Dyserythropoietic, Congenital / genetics*
  • Anemia, Dyserythropoietic, Congenital / immunology
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Case-Control Studies
  • Child, Preschool
  • Cryopyrin-Associated Periodic Syndromes / genetics
  • Cryopyrin-Associated Periodic Syndromes / immunology
  • Female
  • Hereditary Autoinflammatory Diseases / genetics
  • Hereditary Autoinflammatory Diseases / immunology
  • Heterozygote
  • Humans
  • Immunologic Deficiency Syndromes / drug therapy
  • Immunologic Deficiency Syndromes / genetics*
  • Immunologic Deficiency Syndromes / immunology
  • Inflammation / genetics*
  • Inflammation / immunology
  • Interleukin 1 Receptor Antagonist Protein / genetics
  • Interleukin 1 Receptor Antagonist Protein / immunology
  • MAP Kinase Kinase 4 / metabolism
  • Macrophages / immunology*
  • Mitogen-Activated Protein Kinases / metabolism
  • NFATC Transcription Factors / metabolism
  • Nuclear Proteins / genetics*
  • Nuclear Proteins / immunology
  • Osteogenesis / genetics*
  • Osteomyelitis / drug therapy
  • Osteomyelitis / genetics*
  • Osteomyelitis / immunology
  • src-Family Kinases / metabolism

Substances

  • Antibodies, Monoclonal, Humanized
  • Interleukin 1 Receptor Antagonist Protein
  • LPIN2 protein, human
  • NFATC Transcription Factors
  • Nuclear Proteins
  • canakinumab
  • src-Family Kinases
  • Mitogen-Activated Protein Kinases
  • MAP Kinase Kinase 4

Supplementary concepts

  • Deficiency of interleukin-1 receptor antagonist
  • Majeed syndrome

Associated data

  • ClinicalTrials.gov/NCT02974595